Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology
Summarize this article with:
Brendan O'Boyle2.26K FollowersFollow5ShareSavePlay(15min)CommentsSummaryJazz Pharmaceuticals plc is deeply undervalued, trading at 2.4x sales, as the market overlooks its oncology pivot and robust growth catalysts.Ziihera's Phase 3 data surpassing Herceptin signals a transformative 'pipeline in a product' opportunity, targeting multi-billion-dollar HER2+ cancer market.Zepzelca's expanded front-line SCLC approval and Epidiolex's blockbuster trajectory underpin near-term revenue growth and portfolio diversification.I rate JAZZ a Strong Buy, with 2026 a transitional year supporting long-term asymmetric upside as the narrative shifts to growth in oncology. zamrznutitonovi/iStock via Getty Images Jazz Pharmaceuticals plc (JAZZ) is a global biopharmaceutical company headquartered in Dublin, Ireland. While its best-selling neuroscience drug, Xywav, treats narcolepsy, the company is undergoing a robust pivot into oncology with two emerging assets: Ziihera and Zepzelca. This article was written byBrendan O'Boyle2.26K FollowersFollowBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure:I/we have a beneficial long position in the shares of JAZZ either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. All investment opportunities carry inherent risk, including potential loss of principle. Carefully consider your investment objectives, level of experience and risk appetite before making any investment. The above discussion is a framework for investors (both long and short), to understand the factors that will move the underlying security’s price. It is not a prediction and should not be considered investment advice. The author has a beneficial long position in: JAZZ and ONC and may add to the positions.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.